Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS

Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS

Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Me...

Full description

Saved in:
Bibliographic Details
Main Authors: Francesco Bertoldo, Cristina Eller-Vainicher, Vittorio Fusco, Rodolfo Mauceri, Jessica Pepe, Alberto Bedogni, Andrea Palermo, Umberto Romeo, Giuseppe Guglielmi, Giuseppina Campisi
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Journal of Bone Oncology
Subjects:
Osteonecrosis of the jaw
Breast cancer
Prostate cancer
CTIBL
Denosumab
Bisphosphonate
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137424001362
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items